A Clinical Pharmacology Trial of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With Schizophrenia
Understand this study
Who could participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 64 years. Other eligibility criteria apply.
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Withdrawn
- Enrollment listed in the registry
- 0
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- Not clearly listed
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT05119894
- Official title
Show the full official title
A Multicenter, Open-label, Clinical Pharmacology Trial to Determine the Pharmacokinetics, Tolerability, and Safety of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With Schizophrenia
Recruitment & locations
Locations not listed
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Co., Ltd., a pharmaceutical company.
Does this study involve medication?
Yes. The study involves medication, including Brexpiprazole LAI: Dose 1, Brexpiprazole LAI: Dose 2, Brexpiprazole LAI: Dose 3 and Brexpiprazole LAI: Dose 4.
Who can participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 64 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as withdrawn.
